Numerous clinical trials are currently underway exploring the use of pemigatinib in various cancers, including bladder cancer, nonmuscle invasive bladder cancer, recurrent urothelial carcinoma (NCT03914794), pancreatic cancer (NCT05216120), urothelial cancer (NCT04294277), gastrointestinal cancer (NCT05651672), non-small cell lung cancer (NCT05210946), breast cancer (NCT05560334), and, most recently, recurrent GBM and other primary central nervous system tumors with an activating FGFR1-3 mutation or fusion/rearrangement (NCT05267106). This evidence concerns the gene FGFR1 and glioblastoma.